Nautilus Biotechnology Inc (NAUT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.12+20.70%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Nautilus invests in R&D despite losses. It plans to keep costs growth near 15-20% in 2026. The company beat earnings in the last four quarters. This shows some progress in its development.
Nautilus keeps losing money and burning cash. Revenue estimates are very low. Costs may rise faster than planned. The recent sharp stock selloff shows investor doubts.
The market prices in ongoing losses and slow growth. There is no clear consensus on revenue or profit improvement yet. Our view is cautious given the weak financials and recent selloff.
Breaks if: Operating expenses growth exceeds 20% year over year in FY26
Control operating expenses growth to approximately 15-20% year over year compared to 2025 levels, maintaining cost discipline amid development activities.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as NAUT is focused on expanding its proteoform applications portfolio despite being loss-making. The current thesis state is insufficient due to a lack of recent financial performance history.
The market appears to be pricing in high risk, as NAUT is currently loss-making and operates in a high-miss-rate industry. There is a medium confidence level, suggesting that investors may expect volatility based on future earnings guidance.
Management has shown a commitment to controlling operating expenses and sustaining R&D investments, despite ongoing losses. Recent earnings beats indicate some positive momentum, but the overall trajectory remains mixed with high near-term risk.
The long-term thesis hinges on management's ability to advance its product portfolio and maintain cost discipline. Additionally, sector performance, particularly from leading companies, will be crucial in influencing NAUT's growth prospects.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of last 3 quarters including 2025-Q4 guidance. Actual operating expenses decreased 7% in 2026-Q2 and 14% in 2026-Q1 compared to prior year periods, contrary to the expected 15-20% increase. Management is maintaining cost discipline with expenses trending downward, indicating limited progress toward the guided expense growth but consistent cost control.
“Operating expenses were $15.9 million, a 7% decrease compared to prior year period.”
“Operating expenses were $16.1 million, a 14% decrease compared to prior year period.”
“Guidance expects operating expenses to increase by approximately 15-20% year over year compared to 2025.”
Breaks if: Revenue fails to grow beyond $700K in FY26 or $7.65M in FY27
Breaks if: Net losses increase significantly beyond -$14.7M in 2026-Q1
In the next 1 to 3 years, NAUT's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.